4 research outputs found
High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors
The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was
developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57 617
compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits
demonstrated that one series did not return active compounds, whereas three series returned active hits. Structure−activity
studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent potential for further development.
The minimum kinase binding pharmacophore was identified, and key examples demonstrated good selectivity for ERK5 over
p38α kinase
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4
Extracellular regulated kinase 5 (ERK5) signalling has been implicated in driving a number of cellular phenotypes including endothelial cell angiogenesis and tumour cell motility. Novel ERK5 inhibitors were identified using high throughput screening, with a series of pyrrole-2-carboxamides substituted at the 4-position with an aroyl group being found to exhibit IC 50 values in the micromolar range, but having no selectivity against p38α MAP kinase. Truncation of the N-substituent marginally enhanced potency (∼3-fold) against ERK5, but importantly attenuated inhibition of p38α. Systematic variation of the substituents on the aroyl group led to the selective inhibitor 4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (IC 50 0.82 μM for ERK5; IC 50 > 120 μM for p38α). The crystal structure (PDB 5O7I) of this compound in complex with ERK5 has been solved. This compound was orally bioavailable and inhibited bFGF-driven Matrigel plug angiogenesis and tumour xenograft growth. The selective ERK5 inhibitor described herein provides a lead for further development into a tool compound for more extensive studies seeking to examine the role of ERK5 signalling in cancer and other diseases